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Abstract
Background: Repeatedly hospitalized patients with acute exacerbation of  chronic obstructive pulmonary disease (AECOPD) 
are often exposed to more antibiotics, but the distribution of  pathogenic bacteria in these patients is poorly understood. The 
objectives of  this study were to analyze the distribution of  pathogenic bacteria and the risk factors associated with multidrug-re-
sistant (MDR) bacteria infection in early re-admission patients with AECOPD.
Methods: We retrospectively reviewed charts for patients with AECOPD admitted to our hospital between January 2011 and 
November 2012. The early re-admission group and non-early readmission group were determined by whether patients were 
readmitted within 31 days after discharge. Detection of  potentially pathogenic microorganisms (PPMs) and MDR bacteria were 
analyzed. Logistic regression analysis was performed to identify independent risk factors for MDR bacteria infection.
Results: PPMs were isolated from 230 (32.0%) cases of  respiratory tract specimens; MDR bacteria accounted for 24.7% 
(57/230). Pseudomonas aeruginosa (43.7%), Klebsiella pneumoniae (15.6%), and Acinetobacter baumannii (12.5%) were the top three 
PPMs in the early readmission group, while the top three PPMs in the non-early readmission group were K. pneumoniae (23.7%), 
P. aeruginosa (21.2%), and Streptococcus pneumoniae (17.1%). Multivariate analysis showed that use of  antibiotics within 2 weeks 
(odds ratio [OR] 8.259, 95% confidence interval [CI] 3.056-22.322, p = 0.000) was the independent risk factor for MDR bacteria 
infection.
Conclusion: Non-fermentative Gram-negative bacilli (NFGNB) and enterobacteria were the predominant bacteria in early read-
mission patients with AECOPD. The detection rate of  MDR bacteria was high which was related to the use of  antibiotics within 
2 weeks before admission in these patients.  
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Chronic obstructive pulmonary disease (COPD) is a 
common chronic airway disease, and is characterized by 
persistent airflow limitation that is usually progressive. 
COPD is a leading cause of  morbidity, mortality, and uti-
lization of  health care resources worldwide1,2. In China, 
the incidence of  COPD is 8.2% in the population over 
the age of  403, so the number of  COPD patients in China 
is estimated to be close to 43 million. Acute exacerbation 
is an important clinical course in patients with COPD. 
On average, acute exacerbation of  COPD (AECOPD) 
rates are approximately one to two per patient-year; with 
hospitalization averaging approximately 0.1 to 0.2 per pa-
tient-year4. Acute exacerbation is the predominant cause 
of  hospitalization and death, and is also the main expen-
diture component of  medical expenses in patients with 
COPD. For example, in-hospital mortality of  AECOPD 
in the United States was 4.3% in 2006, with mean costs 
of  9,545 USD per patient for hospitalization5. According 
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to an epidemiological study, the cost of  AECOPD for an 
inpatient in the People’s Republic of  China has been 1692 
USD a year6. 
AECOPD is mostly caused by bacterial infection of  the 
trachea and bronchi. The bacterial load was increased in 
patients with AECOPD and at least 50% of  the patients 
had a high concentration of  bacteria in the lower respira-
tory tract7. Up to 80% of  AECOPD is caused by micro-
bial pathogens, including bacteria, viruses, atypical bacte-
ria, and fungi8,9, but the usage of  antibiotics in AECOPD 
is more extensive than expected in the clinical practice10. 
Although large-scale, multi-center studies about the bac-
terial etiology of  AECOPD are lacking, the existing re-
search revealed that the distribution of  pathogenic bac-
teria in AECOPD was related to the severity of  airflow 
limitation. The common pathogenic bacteria of  com-
munity acquired respiratory tract infection, such as Hae-
mophilus influenzae and Streptococcus pneumoniae, were mainly 
found in mild to moderate AECOPD patients, but Pseudo-
monas aeruginosa was more common in patients with severe 
COPD7,9,11,12. Due to the heterogeneity of  patients with 
COPD, the patients with similar forced expiratory vol-
ume in one second (FEV1) percentage of  the predicted 
value may have different clinical status. Global Initiative 
for Chronic Obstructive Pulmonary Disease (GOLD) 
2011 recommended a new comprehensive assessment 
method, covering the degree of  airflow limitation, symp-
toms, acute exacerbations, and comorbidities. Patients 
were divided into A, B, C, and D groups by the former 
three, but research about the distribution of  pathogenic 
bacteria in each group was lacking. 
The unplanned readmission rate within 31 days for the 
same or related disease is one of  the medical quality in-
dex evaluation criteria in the China Healthcare Quality 
Indicators System (CHQIS). The early readmission rate 
of  COPD in five general hospitals in Beijing was 2.67% 
to 6.3%13 - lower than the 30 days readmission rate of  
13.6% to 24.2% in other countries or regions14-16. In a 
previous study, the 31 days readmission rate for AE-
COPD was 6.8%17. 
The risk of  readmission within 31 days is associated with 
the severity of  the disease, and these patients are often ex-
posed to more antibiotics, but the distribution of  patho-
genic bacteria in these patients is poorly understood so 
far. This study aimed to analyze the distribution charac-
teristics, drug resistance of  pathogenic bacteria, and risk 
factors associated with multidrug-resistant (MDR) bacte-
ria infection in early readmission patients with AECOPD, 
which may provide reference for the clinical practice. 
Materials and methods
Patients
Charts for patients with AECOPD who were discharged 
from Taizhou Hospital of  Wenzhou Medical University 
(Zhejiang, P. R. China) over a 23-month period between 
January 1, 2011 to November 30, 2012 were retrospec-
tively reviewed. The diagnosis of  COPD was based on 
patients with long-term smoking and other risk factors, 
history of  chronic cough, expectoration, and dyspnea. 
Physical examination showed signs of  emphysema, chest 
X-ray or computer tomography (CT) showed the signs 
of  chronic bronchitis and emphysema, and blood gas 
analysis was associated with varying degrees of  hypox-
emia and/or increased carbon dioxide pressure. Some 
patients completed spirometric tests before admission or 
during hospitalization which met the GOLD criteria18 for 
COPD. Exclusion criteria were (1) other lung disorders 
such as asthma, lung cancer, bronchiectasis, active tuber-
culosis, pneumothorax, or pleural effusion, and (2) Chest 
X-ray or CT showed shadow of  pulmonary exudation. 
Data collection
We selected patients with a primary diagnosis of  COPD 
using international classification of  diseases (ICD) cod-
ing (ICD-9: 490-492, 494-496) from the information and 
electronic medical record system of  Taizhou Hospital. 
We collected the patient’s demographics, comorbidities, 
and bacteriological test results (17). Arterial partial pres-
sure of  oxygen (PaO2) and arterial partial pressure of  
carbon dioxide (PaCO2) were recorded according to the 
last blood test results during hospitalization. Patients had 
undergone intubation and mechanical ventilation, which 
was defined as within 6 months of  this hospitalization. 
The interval between discharge and readmission was re-
corded for the readmitted patients, and we confirmed the 
same patient by the same hospital medical record number 
and name. The early readmission group and non-early 
readmission group were determined by whether patients 
were readmitted within 31 days after discharge. Study de-
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sign has been approved by the ethics committee of  the 
Taizhou Hospital of  Zhejiang Province, China. Written 
informed consent was not required because of  the retro-
spective nature of  the investigation.
Bacteriological study
Qualified sputum samples (10 squamous cells and > 25 
leukocytes per low-power field) were collected on the 
day of  admission or the next morning. All samples were 
plated onto blood agar, chocolate agar, and MacConkey 
agar within 4 hours of  being collected, and the growth of  
bacteria was observed within 24-48 h. VITEK® 2 COM-
PACT 60 automatic microorganism analyzer (bioMérieux, 
France) and its corresponding identification card were 
used for strain identification. Drug susceptibility testing 
and the results were interpreted using the 2008 criteria of  
the Clinical and Laboratory Standards Institute (CLSI)19. 
Classification of  potentially pathogenic microorganisms 
(PPMs) or non-PPMs depended on the description in 
the literature20. Viridans group streptococci, Neisseria species, 
and Candida species were considered non-PPMs. MDR 
bacteria were judged by the international experts’ recom-
mendation relating to the provisional standard definition 
of  drug resistant bacteria21.
Statistical analysis
All data were analyzed by SPSS 21.0. Numerical variables 
were analyzed by non-parametric test, and chi-squared 
test was used for categorical variables. A P of  <0.05 was 
accepted as indicating a statistically significant difference. 
The MDR bacteria isolated from sputum samples were 
regarded as dependent variables, and the indicators with 
statistically significant difference in univariate analysis 
were considered as independent variables. Finally, mul-
tivariate logistic regression analysis was performed to 
determine the independent risk factors associated with 
MDR bacteria infection in AECOPD patients. 
Results
Patient characteristics
Between January 1, 2011 to November 30, 2012, 515 pa-
tients who were admitted to our hospital with AECOPD 
met the inclusion criteria for the study. The total num-
ber of  AECOPD admissions during this time period was 
718 cases. Baseline characteristics of  patients are shown 
in Table 1. The age of  the patients ranged from 47 to 90 
years, with an average of  73.31 ± 7.657 years. Four hun-
dred and eleven patients were male (79.8%) and 104 pa-
tients were female (20.2%). Sixty one cases were readmit-
ted within 31 days after discharge which met our criteria 
for early readmission. The interval between discharge and 
early readmission was from 2 to 31 days, with an average 
of  15.16 ± 7.27 days, and 10 cases were readmitted within 
7 days after discharge (10/61, 16.4%). One hundred cases 
had a history of  antibiotic treatment within 2 weeks be-
fore admission, and 41 cases had received intubation and 
mechanical ventilation within 6 months of  this hospital-
ization (Table 1).
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Table 1. Baseline characteristics of patients in two  
groups admitted with AECOPD. 
 
Characteristics 
Early readmissions (n = 
61) 
Non-early readmissions 
(n = 657) 
p value 
Gender (male/female) 55/6 529/128 0.064 
Age (years) 72.52 ± 8.555 73.73 ± 7.551 0.239 
Use of antibiotics within 2 
weeks before admission (%) 
23 (37.7%) 77 (11.7%) 0.000 
Have received intubation 
and mechanical ventilation 
10 31 0.001 
PaO2 (mmHg) 63.38 ± 8.091 64.39 ± 8.981 0.394 
PaCO2 (mmHg) 62.41 ± 9.155 58.05 ± 10.589 0.001 
PPMs (%) 32 (52.4%) 198 (30.1%) 0.000 
MDR bacteria (%) 14 (22.9%) 43 (6.5%) 0.000 
Data are presented as mean ± standard deviation.  
PPMs, potentially pathogenic microorganisms; MDR, multidrug-resistant. 
 Distribution of  PPMs and MDR bacteria
PPMs were isolated from 230 cases of  respiratory tract 
specimens, with 32.0% (230/718) of  detection rate. The 
top five bacteria were P. aeruginosa (56 cases, 24.3%), Kleb-
siella pneumoniae (52 cases, 22.6%), S. pneumoniae (36 
cases, 15.6%), Acinetobacter baumannii (28 cases, 12.1%), 
and Escherichia coli (12 cases, 5.2%), respectively (Table 
2). MDR bacteria were isolated from 57 cases of  respi-
ratory tract specimens, accounting for 24.7% of  total 
PPMs (57/230). Non-fermentative Gram-negative bacilli 
(NFGNB) such as A. baumannii (15 cases, 26.3%) and P. 
aeruginosa (12 cases, 21.1%) were the predominant MDR 
bacteria, followed by K. pneumoniae (8 cases, 14.0%) and E. 
coli (4 cases, 7.02%) which belonged to Extended-Spec-
trum Beta-Lactamase (ESBL)-producing Enterobacteria-
ceae. Among Gram-positive cocci, methicillin-resistant 
Staphylococcus aureus (MRSA) (5 cases, 8.77%) and En-
terococcus faecium (2 cases, 3.51%) were the common MDR 
bacteria (Table 2).
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Table 2. Distribution of PPMs and MDR bacteria in 230 
cases of sputum samples with AECOPD 
 
Bacterial species Cases of PPMs (%) Cases of MDR (%) 
Pseudomonas aeruginosa 56 (24.3) 12 (21.1) 
Klebsiella pneumoniae 52 (22.6) 8 (14.0) 
Streptococcus pneumoniae 36 (15.6) 0 (0.00) 
Acinetobacter baumannii 28 (12.1) 15 (26.3) 
Escherichia coli 12 (5.2) 4 (7.02) 
Staphylococcus aureus 10 (4.3) 5 (8.77) 
Haemophilus influenzae 10 (4.3) 0 (0.00) 
Moraxella catarrhalis 6 (2.6) 0 (0.00) 
Enterobacter cloacae 5 (2.1) 1 (1.75) 
Stenotrophomonas 
maltophilia 3 (1.3) 3 (5.26) 
Enterococcus faecium 2 (0.8) 2 (3.51) 
Burkholderia cepacia 2 (0.8) 2 (3.51) 
Staphylococcus haemolyticus 1 (0.4) 0 (0.00) 
Staphylococcus epidermis 1 (0.4) 0 (0.00) 
Flavobacterium 1 (0.4) 1 (1.75) 
P. aeruginosa + A. baumannii 3 (1.3) 3 (5.26) 
P. aeruginosa + S. aureus 1 (0.4) 1 (1.75) 
K. pneumoniae + A. baumannii 1 (0.4) 1 (1.75) 
Total 230 (100) 57 (100) 
PPMs, potentially pathogenic microorganisms; MDR, multidrug-resistant. 
Distribution of  pathogenic bacteria in two groups of  
AECOPD
The detection rate of  PPMs in the early readmission 
group was higher than that in the non-early readmission 
group (P = 0.000), with 52.4% and 30.1%, respectively 
(Table I). The distribution of  PPMs was different in the 
two groups. In the early readmission group, the top three 
bacteria were P. aeruginosa (14 cases, 43.7%), K. pneumo-
niae (5 cases, 15.6%), and A. baumannii (4 cases, 12.5%), 
but K. pneumoniae (47 cases, 23.7%), P. aeruginosa (42 cases, 
21.2%) and S. pneumoniae (34 cases, 17.1%) were the top 
three PPMs in the non-early readmission group (Table 3). 
Compared with the non-early readmission group, isola-
tion of  NFGNB in early readmission group, especially P. 
aeruginosa (P = 0.006), were much higher, while Gram-pos-
itive cocci were relatively low (P = 0.002) (Table 3). The 
detection rate of  MDR bacteria in the early readmission 
group (14/61, 22.9%) was higher than non-early readmis-
sion group (43/657, 6.5%) (P = 0.000) (Table 1). 
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Table 3. Distribution of pathogenic bacteria in the early readmission and non-
early readmission group with AECOPD 
 
PPMs Early readmissions (n = 32) 
Non-early 
readmissions (n = 
198) 
p value 
Traditional pathogenic bacteria 
of community 3 (9.3%) 49 (24.7%) 0.054 
  S. pneumoniae 2 (6.2%) 34 (17.1%) 0.115 
NFGNB 19 (59.3%) 71 (35.8%) 0.011 
  P. Aeruginosa 14 (43.7%) 42 (21.2%) 0.006 
  A. baumannii 4 (12.5%) 24 (12.1%) 1.000 
Enterobacteriaceae 7 (21.8%) 62 (31.3%) 0.280 
  K. pneumoniae 5 (15.6%) 47 (23.7%) 0.309 
Gram-positive cocci (include S. 
pneumoniae) 4 (12.5%) 46 (23.2%) 0.002 
Mixed infection 1 (3.1%) 4 (2.0%) 1.000 
Traditional pathogenic bacteria of community, including S. pneumoniae, H. influenzae and M 
catarrhalis; NFGNB, non-fermentative Gram-negative bacilli; Gram-positive cocci, including S. 
Aureus, S. haemolyticus, S. epidermis and S. pneumoniae.  
Risk factors associated with MDR bacteria infection
Two hundred and thirty cases of  PPMs isolated from re-
spiratory tract specimens were divided into MDR bac-
teria infection group (57 cases) and non-MDR bacteria 
infection group (173 cases). Compared with non-MDR 
bacteria infection group, MDR bacteria infection group 
had higher levels of  PaCO2, more use of  antibiotics with-
in 2 weeks, and more frequent unplanned early re-admis-
son cases (Table 4). Based on the results of  univariate 
analysis, PaCO2, use of  antibiotics within 2 weeks, and 
early re-admission were included in the multivariate anal-
ysis. The logistic regression analysis showed that use of  
antibiotics within 2 weeks (odds ratio [OR] 8.259, 95% 
confidence interval [CI] 3.056-22.322, P = 0.000) was the 
independent risk factor associated with MDR bacteria in-
fection (Table 5).
Table 4. Comparison of patients with AECOPD  
according to MDR bacteria infection status 
 
Characteristics Non-MDR infection (n = 173) MDR infection (n = 57) p value 
Gender (years) 73.09 ± 8.799 73.65 ± 7.873 0.668 
PaO2 (mmHg) 63.08 ± 8.213 65.35 ± 9.129 0.079 
PaCO2 (mmHg) 58.77 ± 10.853 62.46 ± 8.065 0.007 
Intubation and mechanical 
ventilation within 6 months 20 7 0.884 
Use of antibiotics within 2 
weeks 10 19 0.000 
Early readmission 18 14 0.007 
Data are presented as mean ± standard deviation.  
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Discussion
AECOPD is defined as an acute event characterized by 
a worsening of  COPD patient’s respiratory symptoms 
(typically presented with dyspnea, cough, increased spu-
tum production, and/or purulent sputum) that is be-
yond normal day-to-day variations and leads to a change 
in medicaton18. Based on the definition and process of  
disease, infection of  AECOPD generally refers to the 
infection of  the trachea-bronchus, which belongs to the 
field of  lower respiratory tract infections, but is different 
from pneumonia. Strictly, COPD patients with pneumo-
nia belong to COPD combined with community acquired 
pneumonia (CAP), rather than AECOPD, which have 
quite a difference in etiology and prognosis. Therefore, 
the patients with exudative shadow in X-ray or CT on 
admission were excluded in the present study. 
Compared with CAP and hospital acquired pneumonia 
(HAP), research about the microbial etiology of  AE-
COPD were less in the world. Recommendations for the 
use of  antimicrobial agents in GOLD tended to be pro-
grammatic from 2007 edition to 2015 edition, which may 
be related to the complexity and diversity of  individual 
clinical manifestations in COPD. Species of  bacteria were 
associated with the status of  disease, course of  disease, 
lung function, and previous treatment. H. influenzae (in-
cluding Haemophilus parainfluenzae), S. pneumoniae, and 
M. catarrhalis were mostly found in mild COPD patients 
with exacerbation, while P. aeruginosa was more common 
in patients with severe airflow limitation and A. baumannii 
was related to the prolonged hospital stay7,11,22. 
Many problems still exist in the detection of  microbial 
etiology in AECOPD, except for patients with artificial 
airway. The reliability of  bacteria detected from sputum 
via spitting through the mouth was under suspicion be-
cause it may be affected by oral bacterial colonization, 
but sputum bacterial culture was still the most commonly 
used method for diagnosis and treatment in the clinical 
practice. Bacteria can be isolated from the sputum in 40% 
to 60% of  patients with AECOPD, with the three most 
common pathogens being H. influenzae, M. catarrhalis, and 
S. pneumoniae, followed by P. aeruginosa, Enterobacteria-
ceae, S. aureus, and H. parainfluenzae7,8,23. Recently, a large 
multicenter study in China showed that 331 pathogenic 
bacterial strains (37.4%) were isolated from 844 patients 
with AECOPD. Gram-negative bacilli accounted for the 
78.8% of  the total strains, and the predominant bacteria 
were P. aeruginosa, K. pneumoniae, and H. influenzae; 15% of  
which were Gram-positive cocci, including S. pneumoniae, 
and S. Aureus24.
In our study, P. aeruginosa, K. pneumoniae, and S. pneumo-
niae were the predominant PPMs isolated from sputum 
culture of  patients, while H. influenzae and M. catarrha-
lis (which belong to conventional pathogenic bacteria of  
community acquired respiratory tract infection) account-
ed for a low proportion, which may attribute to that all 
the patients were hospitalized and the degree of  airflow 
limitation was severe in this group. The distribution of  
major pathogens in this study, including P. aeruginosa and 
Enterobacteriaceae, is similar to the main clinically isolated 
strains in the domestic homogeneous patients of  Chi-
na, in addition to many research results throughout the 
world8,20,22-25.
Previous studies have found that the risk of  readmission 
for AECOPD is related to factors including the frequen-
cy of  acute exacerbations in the previous year, FEV1%, 
African Health Sciences Vol 19 Issue 2, June, 2019 2079
low body mass index, PaCO2, chronic cor pulmonale, 
short duration of  hospitalization, hyperglycemia, and hy-
poproteinemia13-16,26. In our research data, compared with 
the non-early re-admission group, the early readmission 
group demonstrated higher levels of  PaCO2, percentage 
of  antibiotic treatment within 2 weeks, and percentage of  
intubation and mechanical ventilation within 6 months. 
The detection rate of  PPMs and the percentage of  MDR 
bacteria in the early re-admission group were higher than 
the non-early re-admission group. Simultaneously, the 
distribution of  PPMs was different in the two groups. In 
the early readmission group, the top three bacteria were 
P. aeruginosa, K. pneumoniae1, and A. baumannii, but K. 
pneumoniae, P. aeruginosa, and S. pneumoniae were the top 
three PPMs in the non-early readmission group. Com-
pared with the non-early re-admission group, isolation 
of  NFGNB in the early re-admission group, especially 
P. aeruginosa, was much higher, while Gram-positive coc-
ci isolation was relatively low. The MDR bacteria were 
more common in the early re-admission group than the 
non-early readmission group. The differences in the dis-
tribution of  PPMs and the detection rate of  MDR bacte-
ria may be related to the application of  antibiotics and the 
severity of  the disease itself. 
Previous studies have indicated that the use of  antibiotics 
and endotracheal intubation were the independent risk 
factors for the infection of  MDR bacteria27. This study 
showed that the detection rate of  MDR bacteria was high 
in the early readmission group, and multivariate regres-
sion analysis revealed that infection of  MDR bacteria was 
associated with use of  antibiotics within 2 weeks. Antibi-
otics have been considered as an independent risk factor 
for MDR infection in AECOPD; the occurrence and de-
velopment of  MDR bacteria are a serious consequence 
of  the wide use, especially the unreasonable application 
of  antibiotics27,28. 
There are limitations of  this study. Reliance on clinical 
diagnosis rather than international guideline diagnosis 
for COPD (GOLD criteria) is a weakness. The patients 
with AECOPD who did not meet the criteria of  admis-
sion were not included in our study because all of  the 
patients were hospitalized. Few women were identified in 
the review, which may reflect under-diagnosis or a lower 
prevalence of  COPD in women in China. This was also 
a retrospective study, and confirmation of  the findings 
should be sought in prospective studies. 
 
Conclusion
NFGNB and entero bacteria accounted for a higher pro-
portion in unplanned early readmission patients with AE-
COPD, while the detection rate of  MDR bacteria was 
also high. For such patients, more attention should be 
paid in detecting bacterial etiology and the results of  drug 
susceptibility testing, strictly mastering the indications for 
application of  antibiotics, and reducing the possibility of  
MDR bacteria infection in patients with AECOPD.
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